Lyme disease is a chronic infectious disease caused by the bacteria, spirochete of the Borrelia type. Skin, nervous system, musculoskeletal system and heart may be involved in the course of the disease. The prognosis for properly treated Lyme disease is usually good. However, in about 5% of patients so called Post-Lyme disease syndrome (PLSD) develops. It is defined as a syndrome of subjective symptoms persisting despite proper treatment of Borrelia burgdorferi infection. The most common symptoms include: fatigue, muscle and joint pain, and problems with memory and concentration. Pathogenesis of PLDS remains unknown. The differential diagnosis should include neurological, rheumatic and mental diseases. Till now there is no causative treatment of PLDS. In relieving symptom rehabilitation, painkillers, anti-inflammatory and antidepressants medicines are recommended. Emotional and psychological supports are also necessary. Non-specific symptoms reported by patients with post- Lyme disease syndrome raise the suspicion of other pathologies. This can lead to misdiagnosis and implementation of unnecessary, potentially harmful to the patient's therapy. An increase in tick-borne diseases needs to increase physicians awareness of these issues.
Download full-text PDF |
Source |
---|
mBio
January 2025
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
In , the causative agent of Lyme disease, differential gene expression is primarily governed by the alternative sigma factor RpoS (σ). Understanding the regulation of RpoS is crucial for elucidating how is maintained throughout its enzootic cycle. Our recent studies have shown that the homolog of Fur/PerR repressor/activator BosR functions as an RNA-binding protein that controls the mRNA stability.
View Article and Find Full Text PDFJ Exp Zool A Ecol Integr Physiol
January 2025
Global Health and Interdisciplinary Disease Research Center and Center for Genomics, College of Public Health, Interdisciplinary Research Building (IDRB), Tampa, Florida, USA.
Mice in the genus Peromyscus are abundant and geographically widespread in North America, serving as reservoirs for zoonotic pathogens, including Borrelia burgdorferi (B. burgdorferi), the causative agent of Lyme disease, transmitted by Ixodes scapularis ticks. While the white-footed mouse (Peromyscus leucopus (P.
View Article and Find Full Text PDFBrain Behav Immun Health
February 2025
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Background And Objective: Lyme disease, caused by , presents major health challenges worldwide, leading to serious neurological and musculoskeletal issues that impact patients' lives and healthcare systems. This systematic review and meta-analysis aim to determine the prevalence and link between Lyme disease and these complications, aiming to enhance clinical and public health approaches.
Methods: We systematically searched PubMed, EMBASE, and Web of Science up until April 01, 2024, to find studies reporting the prevalence and severity of neurological and musculoskeletal complications associated with Lyme disease.
Cureus
December 2024
Internal Medicine, Central Michigan University, Saginaw, USA.
Lyme neuroborreliosis can present with isolated neurological manifestations, posing diagnostic challenges, especially in the absence of hallmark dermatological symptoms like erythema migrans. This case highlights a patient with isolated cervical radiculopathy due to Lyme neuroborreliosis, presenting without systemic features such as fever, arthralgia, or rash. The diagnosis was confirmed through serological testing, with positive findings on the Western blot.
View Article and Find Full Text PDFJ Clin Pharmacol
January 2025
Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Amoxicillin is commonly used to treat erythema migrans in the first stage of Lyme disease in children, with a recommended dose of 50 mg/kg/day, administered three times a day (q8h). This model-based simulation study aimed to determine whether splitting the same daily dose into two administrations (q12h) would provide comparable drug exposure. A pharmacokinetic model suitable for a pediatric population (age: 1 month to 18 years, weight: 4-80 kg) was selected through a literature review.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!